After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Akero Therapeutics Inc is $3.61B. A total of 15.24 million shares were traded on the day, compared to an average of 718.90K shares.
In the most recent transaction, CATRIONA YALE bought 53,591 shares of AKRO for 26.18 per share on Jan 27 ’25. In a previous transaction on Jan 27 ’25, CATRIONA YALE bought 69,073 shares at 26.18 per share.
Among the insiders who bought shares, PATRICK D LAMY acquired of 6,000 shares on Jan 27 ’25 at a per-share price of $26.18. In another insider transaction, Andrew Cheng bought 120,000 shares at $57.03 per share on Jan 27 ’25.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, AKRO has a high of $37.00 and a low of $15.32.
As of this writing, AKRO has an earnings estimate of -$1.13 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$1.07 per share and a lower estimate of -$1.19.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $10.61, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 4.83.
